DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Drug Target Review

JUNE 12, 2023

With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. The system optimised the molecules that were most likely to succeed in terms of potency, metabolic stability, synthetic accessibility, and more.

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

Drug Target Review

SEPTEMBER 20, 2023

How AI/ML technology has accelerated drug discovery Although AI for drug discovery (AIDD) can be viewed as being in the initial phases of development and acceptance, compounds discovered using AIDD platforms are already entering clinical trials. To really benefit from AI, the pharmaceutical industry must be more open to data sharing.

Drugs 105

Drugs Metabolic Stability Computational Chemistry Pharmaceuticals 105

Metabolite Tales Blog

JULY 5, 2023

Still, of the 34 macrocycles currently in clinical trials, only 18% are de novo designed. Not only this, the reduction in rotatable bonds and consequent reduction in susceptibility to metabolism is an additional benefit [4]. Several metabolites were observed with an S -oxide and an acyl glucuronide being major human metabolites.

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52

Metabolite Tales Blog

JULY 5, 2023

Still, of the 34 macrocycles currently in clinical trials, only 18% are de novo designed. Not only this, the reduction in rotatable bonds and consequent reduction in susceptibility to metabolism is an additional benefit [4]. Several metabolites were observed with an S -oxide and an acyl glucuronide being major human metabolites.

Metabolic Stability 52

Metabolic Stability Drugs FDA Approval Treatment 52

Drug Target Review

JANUARY 16, 2025

Phase III trials for MK-0616 commenced in the second half of 2023. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. Cyclic Peptide Design, Chapter 2: Strategies to Enhance Metabolic Stabilities. These drugs, including grazoprevir and vaniprevir, were the result of macrocyclisation of acyclic precursors.

Drug Development 52

Drug Development Small Molecule Drugs FDA Approval 52